Market Overview

Kaskela Law LLC Announces Investigation of IVERIC bio, Inc. on Behalf of Stockholders


Kaskela Law LLC has commenced an investigation of IVERIC bio, Inc. ("IVERIC" or the "Company") (NASDAQ:ISEE), formerly known as Ophthotech Corp., on behalf of the Company's stockholders.

IVERIC stockholders who purchased shares of the Company's stock before December 12, 2016 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 – 1740 to discuss this investigation and their legal rights and options. Additional information about this investigation may also be found at

In 2017, a shareholder securities fraud complaint was filed against the Company in federal court on behalf of certain purchasers of IVERIC's common stock. Among other things, the shareholder complaint alleges that IVERIC violated the federal securities laws by making a series of materially false and misleading statements to investors regarding the parameters and results of clinical studies for Fovista.

Kaskela Law LLC is investigating whether IVERIC's executive officers and/or directors breached their fiduciary duties to the Company and its stockholders in connection with the above alleged misconduct.

Kaskela Law LLC prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit This notice may constitute attorney advertising in certain jurisdictions.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at